Department of Cardiothoracic and Vascular Surgery & Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark
Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Aarhus, Denmark.
BMJ Open. 2022 Mar 9;12(3):e054236. doi: 10.1136/bmjopen-2021-054236.
Pleural empyema is a frequent disease with a high morbidity and mortality. Current standard treatment includes antibiotics and thoracic ultrasound (TUS)-guided pigtail drainage. Simultaneously with drainage, an intrapleural fibrinolyticum can be given. A potential better alternative is surgery in terms of video-assisted thoracoscopic surgery (VATS) as first-line treatment. The aim of this study is to determine the difference in outcome in patients diagnosed with complex parapneumonic effusion (stage II) and pleural empyema (stage III) who are treated with either VATS surgery or TUS-guided drainage and intrapleural therapy (fibrinolytic (Alteplase) with DNase (Pulmozyme)) as first-line treatment.
A national, multicentre randomised, controlled study. Totally, 184 patients with a newly diagnosed community acquired complicated parapneumonic effusion or pleural empyema are randomised to either (1) VATS procedure with drainage or (2) TUS-guided pigtail catheter placement and intrapleural therapy with Actilyse and DNase. The total follow-up period is 12 months. The primary endpoint is length of hospital stay and secondary endpoints include for example, mortality, need for additional interventions, consumption of analgesia and quality of life.
All patients provide informed consent before randomisation. The research project is carried out in accordance with the Helsinki II Declaration, European regulations and Good Clinical Practice Guidelines. The Scientific Ethics Committees for Denmark and the Danish Data Protection Agency have provided permission. Information about the subjects is protected under the Personal Data Processing Act and the Health Act. The trial is registered at www.
gov, and monitored by the regional Good clinical practice monitoring unit. The results of this study will be published in peer-reviewed journals and presented at various national and international conferences.
NCT04095676.
脓胸是一种发病率和死亡率都很高的常见疾病。目前的标准治疗包括抗生素和超声(TUS)引导下的猪尾引流。同时,可在引流的同时给予胸腔内纤维蛋白溶解剂。在手术方面,电视辅助胸腔镜手术(VATS)作为一线治疗具有潜在的优势。本研究旨在确定接受 VATS 手术或 TUS 引导下引流和胸腔内治疗(纤维蛋白溶解剂(阿替普酶)联合脱氧核糖核酸酶(Pulmozyme))作为一线治疗的诊断为复杂类肺炎性胸腔积液(II 期)和脓胸(III 期)患者的治疗结果的差异。
这是一项全国性的、多中心的随机对照研究。共纳入 184 例新发社区获得性复杂类肺炎性胸腔积液或脓胸患者,随机分为(1)VATS 引流组或(2)TUS 引导下猪尾导管置管和胸腔内阿替普酶联合脱氧核糖核酸酶治疗组。总的随访时间为 12 个月。主要终点是住院时间,次要终点包括死亡率、需要额外干预、镇痛药消耗和生活质量等。
所有患者在随机分组前均提供知情同意。研究项目符合赫尔辛基 II 宣言、欧洲法规和良好临床实践指南。丹麦科学伦理委员会和丹麦数据保护局已批准该项目。受试者的信息受个人数据处理法和卫生法的保护。该试验在 www.clinicaltrials.gov 上注册,并由地区良好临床实践监测单位进行监测。该研究的结果将发表在同行评议的期刊上,并在各种国内和国际会议上展示。
NCT04095676。